Evidence map›Paper›PMID 38731802›Full record

ArticleInternational journal of molecular sciences2024

Enhanced ALOX12 Gene Expression Predicts Therapeutic Susceptibility to 5-Azacytidine in Patients with Myelodysplastic Syndromes.

Taichi Matsumoto, Yuichi Murakami, Nao Yoshida-Sakai, Daisuke Katsuchi, Kuon Kanazawa, Takashi Okamura, Yutaka Imamura, Mayumi Ono, Michihiko Kuwano

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Taichi MatsumotoBasic Medical Research Unit, St. Mary's Research Center, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.ORCID 0000-0001-5301-1481
Yuichi MurakamiBasic Medical Research Unit, St. Mary's Research Center, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.
Nao Yoshida-SakaiDepartment of Hematology, St. Mary's Hospital, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.
Daisuke KatsuchiBasic Medical Research Unit, St. Mary's Research Center, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.
Kuon KanazawaBasic Medical Research Unit, St. Mary's Research Center, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.
Takashi OkamuraDepartment of Hematology, St. Mary's Hospital, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.
Yutaka ImamuraDepartment of Hematology, St. Mary's Hospital, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.
Mayumi OnoBasic Medical Research Unit, St. Mary's Research Center, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.
Michihiko KuwanoBasic Medical Research Unit, St. Mary's Research Center, 422, Tsubuku-Honmachi, Kurume 850-8543, Fukuoka, Japan.

Funding

Japan Society for the Promotion of Science 21K06703
6 · The paper itself

Abstract

5-azacytidine (AZA), a representative DNA-demethylating drug, has been widely used to treat myelodysplastic syndromes (MDS). However, it remains unclear whether AZA's DNA demethylation of any specific gene is correlated with clinical responses to AZA. In this study, we investigated genes that could contribute to the development of evidence-based epigenetic therapeutics with AZA. A DNA microarray identified that AZA specifically upregulated the expression of 438 genes in AZA-sensitive MDS-L cells but not in AZA-resistant counterpart MDS-L/CDA cells. Of these 438 genes, the

Indexed as

Arachidonate 12-LipoxygenaseAzacitidineDNA MethylationMyelodysplastic SyndromesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedALOX12 protein, humanArachidonate 12-LipoxygenaseAzacitidine5-azacytidineALOX12myelodysplastic syndromes

Identifiers

PMID38731802
PMCPMC11083213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.